Media coverage about Catalent (NYSE:CTLT) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalent earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.2739857744363 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have impacted Accern’s rankings:

Catalent (NYSE CTLT) traded up $1.18 during trading hours on Wednesday, hitting $39.23. The stock had a trading volume of 1,127,129 shares, compared to its average volume of 911,957. The stock has a market capitalization of $5,032.72, a price-to-earnings ratio of 26.49, a PEG ratio of 2.43 and a beta of 1.41. Catalent has a 52-week low of $23.09 and a 52-week high of $43.39. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. The firm had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.16 earnings per share. equities research analysts forecast that Catalent will post 1.46 EPS for the current fiscal year.

Several analysts have issued reports on the company. BidaskClub raised Catalent from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. Wells Fargo & Company upped their target price on Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 20th. Bank of America reaffirmed a “buy” rating and issued a $45.00 target price (up previously from $40.00) on shares of Catalent in a research note on Wednesday, September 20th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $45.00 target price on shares of Catalent in a research note on Tuesday, August 29th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $38.00 target price (up previously from $35.00) on shares of Catalent in a research note on Tuesday, August 29th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $44.25.

In related news, Director Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average price of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/07/catalent-ctlt-earning-somewhat-favorable-media-coverage-analysis-shows.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Stock Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related stocks with our FREE daily email newsletter.